Compare OPAD & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPAD | ALLR |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | 140 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.8M | 26.1M |
| IPO Year | N/A | 2021 |
| Metric | OPAD | ALLR |
|---|---|---|
| Price | $0.62 | $1.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $1.83 | ★ $9.75 |
| AVG Volume (30 Days) | ★ 588.7K | 251.9K |
| Earning Date | 04-30-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $320,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $32.08 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $0.77 |
| 52 Week High | $6.35 | $2.35 |
| Indicator | OPAD | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 38.69 | 50.75 |
| Support Level | $0.60 | $1.51 |
| Resistance Level | $0.90 | $1.80 |
| Average True Range (ATR) | 0.06 | 0.16 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 13.36 | 41.71 |
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services, including mortgage, listing, renovation, and buyer representation services.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.